NO2972131T3 - - Google Patents

Info

Publication number: NO2972131T3
Authority: NO; Norway

Application number

NO14719160A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-11

Filing date

2014-03-13

Publication date

2018-04-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2972131(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-13 Application filed filed Critical

2018-04-21 Publication of NO2972131T3 publication Critical patent/NO2972131T3/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Analytical Chemistry (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO14719160A 2012-09-11 2014-03-13 NO2972131T3 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261699552P	2012-09-11	2012-09-11

Publications (1)

Publication Number	Publication Date
NO2972131T3 true NO2972131T3 (hu)	2018-04-21

Family

ID=50233493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO14719160A NO2972131T3 (hu)	2012-09-11	2014-03-13

Country Status (33)

Country	Link
US (6)	US20140072560A1 (hu)
EP (1)	EP2895188B1 (hu)
JP (3)	JP2015533797A (hu)
KR (2)	KR102250937B1 (hu)
CN (2)	CN110051823A (hu)
AR (1)	AR092532A1 (hu)
AU (2)	AU2013315750B9 (hu)
BR (1)	BR112015005161A2 (hu)
CA (1)	CA2882551A1 (hu)
CL (1)	CL2015000572A1 (hu)
CO (1)	CO7400876A2 (hu)
CY (1)	CY1120062T1 (hu)
DK (1)	DK2895188T3 (hu)
DO (1)	DOP2015000055A (hu)
EA (1)	EA031324B1 (hu)
EC (1)	ECSP15014138A (hu)
ES (1)	ES2657377T3 (hu)
HR (1)	HRP20180182T1 (hu)
HU (1)	HUE036524T2 (hu)
IL (2)	IL237311B (hu)
IN (1)	IN2015KN00452A (hu)
LT (1)	LT2895188T (hu)
MX (2)	MX360044B (hu)
NO (1)	NO2972131T3 (hu)
PE (2)	PE20150996A1 (hu)
PL (1)	PL2895188T3 (hu)
PT (1)	PT2895188T (hu)
RS (1)	RS57013B1 (hu)
SG (1)	SG11201501460RA (hu)
SI (1)	SI2895188T1 (hu)
SM (1)	SMT201800163T1 (hu)
TW (2)	TWI716649B (hu)
WO (1)	WO2014043103A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080311078A1 (en)	2005-06-14	2008-12-18	Gokarn Yatin R	Self-Buffering Protein Formulations
BR112014009131A8 (pt)	2011-10-18	2017-06-20	Coherus Biosciences Inc	formulações de etanercept estabilizadas com meglumina
US10493151B2 (en)	2011-10-18	2019-12-03	Coherus Biosciences, Inc.	Etanercept formulations stabilized with sodium chloride
HUE036524T2 (hu) *	2012-09-11	2018-07-30	Coherus Biosciences Inc	Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept
CA2951766A1 (en) *	2014-06-13	2015-12-17	Lupin Limited	Process for the purification of tnfr:fc fusion protein
ES2733298T3 (es)	2014-07-18	2019-11-28	Sandoz Ag	Cuantificación de TNFR2:Fc plegado erróneamente
WO2016108569A1 (ko) *	2014-12-31	2016-07-07	주식회사 엘지생명과학	목적하는 함량으로 불순물을 포함하는 tnfr-fc 융합 단백질의 제조방법
KR20170138426A (ko)	2015-03-13	2017-12-15	삼성바이오에피스 주식회사	항-tnf-알파 폴리펩티드 조성물 및 그 용도
AU2016355739A1 (en) *	2015-11-18	2018-07-05	Merck Patent Gmbh	Improved protein separation in ion exchange chromatography
EP3377514A1 (en) *	2015-11-18	2018-09-26	Merck Patent GmbH	Opposite ph-salt gradients for improved protein separations
EP3472177B1 (en) *	2016-06-17	2024-08-14	F. Hoffmann-La Roche AG	Purification of multispecific antibodies
AU2017345490B2 (en)	2016-10-21	2022-07-07	Amgen Inc.	Pharmaceutical formulations and methods of making the same
EP3558363A1 (en)	2016-12-21	2019-10-30	Amgen Inc.	Anti-tnf alpha antibody formulations
CA3042126A1 (en)	2018-05-03	2019-11-03	Michael A. Portman	Methods of treating kawasaki disease
CN112876567A (zh) *	2019-11-29	2021-06-01	广东菲鹏制药股份有限公司	Fc融合蛋白及其纯化方法
WO2021220251A1 (en)	2020-05-01	2021-11-04	Kashiv Biosciences, Llc	An improved process of purification of protein
US20240156907A1 (en) *	2021-03-16	2024-05-16	Kashiv Biosciences, Llc	Novel formulation of fusion protein
WO2022234412A1 (en) *	2021-05-03	2022-11-10	Lupin Limited	A process for purification of fc-fusion proteins

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5605690A (en)	1989-09-05	1997-02-25	Immunex Corporation	Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en)	1989-09-05	1995-03-07	Immunex Corporation	DNA encoding tumor necrosis factor-α and -β receptors
EP0417563B1 (de)	1989-09-12	2000-07-05	F. Hoffmann-La Roche Ag	TNF-bindende Proteine
IT1240314B (it)	1989-09-28	1993-12-07	Immunobiology Research Institutes, Inc.	Formulazioni acquose stabilizzate di piccoli peptidi.
ES2251009T3 (es)	1990-06-28	2006-04-16	Sanofi-Aventis Deutschland Gmbh	Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso.
WO1994006476A1 (en)	1992-09-15	1994-03-31	Immunex Corporation	Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0852951A1 (de)	1996-11-19	1998-07-15	Roche Diagnostics GmbH	Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en)	1999-01-05	2007-11-13	Immunex Corporation	Method for producing recombinant proteins
US20040220103A1 (en)	1999-04-19	2004-11-04	Immunex Corporation	Soluble tumor necrosis factor receptor treatment of medical disorders
AU4363200A (en)	1999-04-19	2000-11-02	Immunex Corporation	Soluble tumor necrosis factor receptor treatment of medical desorders
US20010021380A1 (en)	1999-04-19	2001-09-13	Pluenneke John D.	Soluble tumor necrosis factor receptor treatment of medical disorders
BR0108193A (pt)	2000-02-10	2003-02-25	Wyeth Corp	Processo para tratamento ou inibição de dano celular ou morte celular
DK1314437T3 (da)	2000-08-11	2014-07-14	Chugai Pharmaceutical Co Ltd	Stabiliserede antistofindeholdende præparater
CA2438094C (en)	2001-02-23	2011-10-11	Immunex Corporation	Increased recovery of active proteins
PL215168B1 (pl)	2002-02-27	2013-10-31	Immunex Corp	Formulacja polipeptydowa
DE60236025D1 (de) *	2002-08-22	2010-05-27	Vasopharm Biotech Gmbh	Pharmazeutische zusammensetzung enthaltend l-arginin
US20040115263A1 (en)	2002-08-26	2004-06-17	Robertson David W.	Use of bupropion for treating restless legs syndrome
EP1603596B1 (en)	2003-02-28	2008-05-07	Ares Trading S.A.	Liquid formulations of tumor necrosis factor-binding protein tbp-1
EP1607103A1 (en)	2003-03-20	2005-12-21	Eisai Co., Ltd.	Concomitant drug as therapeutic agent for inflammatory bowel disease
RU2006101216A (ru)	2003-08-01	2007-07-20	Амген Инк. (US)	Кристаллические полипептиды 2 фактора некроза опухолей
TWI375679B (en)	2003-10-14	2012-11-01	Hoffmann La Roche	Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
KR101150050B1 (ko) *	2004-02-27	2012-07-05	지이 헬스케어 바이오-사이언시스 에이비	항체 정제 방법
WO2005082377A1 (ja)	2004-03-01	2005-09-09	Ajinomoto Co., Inc.	抗ヒトTNF-α抗体活性低下抑制剤
KR101050585B1 (ko)	2004-03-05	2011-07-19	디에스엠 아이피 어셋츠 비.브이.	연속식 살포 및 교호 접선 흐름에 의한 세포 배양 방법
US20070196364A1 (en)	2004-07-27	2007-08-23	Human Genome Sciences, Inc.	Pharmaceutical Formulation and Process
TWI364458B (en)	2004-08-27	2012-05-21	Wyeth Res Ireland Ltd	Production of tnfr-lg
CA2607697C (en)	2005-05-10	2015-01-06	Biogen Idec Ma Inc.	Treating and evaluating inflammatory disorders
JP5068167B2 (ja)	2005-06-10	2012-11-07	中外製薬株式会社	メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
TWI393575B (zh)	2005-12-20	2013-04-21	必治妥美雅史谷比公司	安定之蛋白質調配物
WO2007076062A2 (en)	2005-12-21	2007-07-05	Wyeth	Protein formulations with reduced viscosity and uses thereof
JP2009525986A (ja)	2006-02-03	2009-07-16	メディミューン，エルエルシー	タンパク質製剤
CA2646508A1 (en)	2006-03-17	2007-09-27	Biogen Idec Ma Inc.	Stabilized polypeptide compositions
MX2008013535A (es)	2006-04-21	2008-10-29	Amgen Inc	Agentes amortiguadores para formulaciones biofarmaceuticas.
EP2081553B1 (en)	2006-10-06	2020-08-12	Amgen Inc.	Stable antibody formulations
AU2007309616B2 (en)	2006-10-20	2011-10-06	Amgen Inc.	Stable polypeptide formulations
CA2666317C (en)	2006-11-03	2013-08-06	Wyeth	Glycolysis-inhibiting substances in cell culture
US20080213282A1 (en)	2006-12-21	2008-09-04	Jaby Jacob	Formulations
US7691980B2 (en)	2007-01-09	2010-04-06	Bio-Rad Laboratories, Inc.	Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
MX2009009240A (es)	2007-03-02	2009-09-08	Wyeth Corp	Uso de cobre y glutamato en el cultivo celular para la produccion de polipeptidos.
EP2014760A1 (en)	2007-06-13	2009-01-14	CMC Biopharmaceuticals A/S	A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
MX2009013593A (es)	2007-06-14	2010-01-20	Biogen Idec Inc	Formulaciones de anticuerpos.
KR20210049186A (ko)	2007-11-30	2021-05-04	애브비 바이오테크놀로지 리미티드	단백질 제형 및 이의 제조방법
CA2717129A1 (en) *	2008-02-29	2009-09-11	Biogen Idec Ma Inc.	Purified immunoglobulin fusion proteins and methods of their purification
WO2009146755A1 (en) *	2008-06-05	2009-12-10	Affibody Ab	Polypeptide
WO2011015926A1 (en) *	2009-08-03	2011-02-10	Avesthagen Limited	A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
EP2462157B1 (en)	2009-08-07	2020-06-17	EMD Millipore Corporation	Methods for purifying a target protein from one or more impurities in a sample
AU2010282733B2 (en)	2009-08-11	2016-07-14	Genentech, Inc.	Production of proteins in glutamine-free cell culture media
EP2490780A4 (en) *	2009-10-20	2014-04-09	Merck Sharp & Dohme	USE OF A MIXED MODE CHROMATOGRAPHY FOR THE DETECTION AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
US20130052195A1 (en)	2009-12-23	2013-02-28	Emergent Product Development Seattle,LLC	Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
RU2644651C2 (ru)	2010-04-26	2018-02-13	Новартис Аг	Среда для культивирования клеток
RU2600847C2 (ru) *	2010-05-10	2016-10-27	Интас Биофармасьютикалс Лимитед	Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
EP2598167B1 (en)	2010-07-30	2015-04-01	Arecor Limited	Stabilized aqueous antibody compositions
EP2606119A1 (en)	2010-08-20	2013-06-26	Wyeth LLC	Cell culture of growth factor-free adapted cells
US20130224855A1 (en)	2010-08-31	2013-08-29	Abhishek Gupta	Culture medium for eukaryotic cells
MX344268B (es) *	2010-10-11	2016-12-09	Abbvie Inc *	Proceso para purificacion de proteinas.
ES2759931T3 (es)	2011-04-20	2020-05-12	Sandoz Ag	Formulaciones líquidas farmacéuticas estables de la proteína de fusión TNFR:Fc
UY34105A (es)	2011-06-03	2012-07-31	Lg Life Sciences Ltd	Formulación líquida estable de etanercept
EA026226B1 (ru)	2011-07-01	2017-03-31	Байоджен Айдек Ма Инк.	Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
CA2952347A1 (en)	2011-07-01	2013-01-10	Amgen Inc.	Mammalian cell culture
CA2840951A1 (en) *	2011-07-08	2013-01-17	Merck Sharp & Dohme Corp.	Methods for purifying fc-fusion protein
KR101454316B1 (ko) *	2011-08-17	2014-10-27	한화케미칼 주식회사	활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
BR112014009131A8 (pt) *	2011-10-18	2017-06-20	Coherus Biosciences Inc	formulações de etanercept estabilizadas com meglumina
US10493151B2 (en) *	2011-10-18	2019-12-03	Coherus Biosciences, Inc.	Etanercept formulations stabilized with sodium chloride
WO2014011672A1 (en) *	2012-07-09	2014-01-16	Coherus Biosciences, Inc.	Etanercept formulations exhibiting marked reduction in sub-visible particles
HUE036524T2 (hu) *	2012-09-11	2018-07-30	Coherus Biosciences Inc	Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept
WO2016015163A1 (en) *	2014-07-31	2016-02-04	Mtt Innovation Incorporated	Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) *	2014-10-16	2016-04-21	Ronald Uphold	Pool Cover Hanger Device

2013
- 2013-09-10 HU HUE13838016A patent/HUE036524T2/hu unknown
- 2013-09-10 EP EP13838016.7A patent/EP2895188B1/en active Active
- 2013-09-10 SI SI201330936T patent/SI2895188T1/en unknown
- 2013-09-10 JP JP2015531311A patent/JP2015533797A/ja active Pending
- 2013-09-10 PE PE2015000316A patent/PE20150996A1/es unknown
- 2013-09-10 KR KR1020207019733A patent/KR102250937B1/ko not_active Expired - Fee Related
- 2013-09-10 RS RS20180095A patent/RS57013B1/sr unknown
- 2013-09-10 PE PE2019002512A patent/PE20200607A1/es unknown
- 2013-09-10 SG SG11201501460RA patent/SG11201501460RA/en unknown
- 2013-09-10 DK DK13838016.7T patent/DK2895188T3/en active
- 2013-09-10 CA CA2882551A patent/CA2882551A1/en active Pending
- 2013-09-10 PT PT138380167T patent/PT2895188T/pt unknown
- 2013-09-10 WO PCT/US2013/058994 patent/WO2014043103A1/en active Application Filing
- 2013-09-10 AU AU2013315750A patent/AU2013315750B9/en not_active Ceased
- 2013-09-10 CN CN201811633164.2A patent/CN110051823A/zh active Pending
- 2013-09-10 PL PL13838016T patent/PL2895188T3/pl unknown
- 2013-09-10 EA EA201590542A patent/EA031324B1/ru unknown
- 2013-09-10 LT LTEP13838016.7T patent/LT2895188T/lt unknown
- 2013-09-10 SM SM20180163T patent/SMT201800163T1/it unknown
- 2013-09-10 BR BR112015005161A patent/BR112015005161A2/pt not_active Application Discontinuation
- 2013-09-10 KR KR1020157009386A patent/KR102133699B1/ko not_active Expired - Fee Related
- 2013-09-10 CN CN201380058650.5A patent/CN104902914B/zh not_active Expired - Fee Related
- 2013-09-10 MX MX2015003090A patent/MX360044B/es active IP Right Grant
- 2013-09-10 IN IN452KON2015 patent/IN2015KN00452A/en unknown
- 2013-09-10 ES ES13838016.7T patent/ES2657377T3/es active Active
- 2013-09-11 TW TW106136921A patent/TWI716649B/zh not_active IP Right Cessation
- 2013-09-11 AR ARP130103250A patent/AR092532A1/es not_active Application Discontinuation
- 2013-09-11 TW TW102132831A patent/TWI609877B/zh not_active IP Right Cessation
- 2013-09-11 US US14/023,736 patent/US20140072560A1/en not_active Abandoned
2014
- 2014-03-13 NO NO14719160A patent/NO2972131T3/no unknown
2015
- 2015-02-19 IL IL237311A patent/IL237311B/en active IP Right Grant
- 2015-03-06 CL CL2015000572A patent/CL2015000572A1/es unknown
- 2015-03-10 DO DO2015000055A patent/DOP2015000055A/es unknown
- 2015-03-10 MX MX2018012749A patent/MX2018012749A/es unknown
- 2015-04-07 CO CO15076746A patent/CO7400876A2/es unknown
- 2015-04-10 EC ECIEPI201514138A patent/ECSP15014138A/es unknown
2017
- 2017-09-29 US US15/720,291 patent/US11001627B2/en active Active
2018
- 2018-01-31 HR HRP20180182TT patent/HRP20180182T1/hr unknown
- 2018-02-13 CY CY20181100172T patent/CY1120062T1/el unknown
- 2018-10-10 AU AU2018247244A patent/AU2018247244B2/en not_active Ceased
- 2018-10-11 JP JP2018192476A patent/JP6913066B2/ja active Active
2019
- 2019-06-17 US US16/443,514 patent/US10954293B2/en active Active
- 2019-06-17 US US16/443,594 patent/US10954294B2/en active Active
- 2019-06-17 US US16/443,688 patent/US10947306B2/en active Active
- 2019-06-17 US US16/443,721 patent/US10954295B2/en active Active
- 2019-06-18 IL IL267452A patent/IL267452B/en active IP Right Grant
2021
- 2021-02-22 JP JP2021025939A patent/JP2021100929A/ja active Pending

Also Published As

Publication number	Publication date
TW201425331A (zh)	2014-07-01
IL267452A (en)	2019-08-29
IL237311B (en)	2019-07-31
BR112015005161A2 (pt)	2017-07-04
IN2015KN00452A (hu)	2015-07-17
US20190300602A1 (en)	2019-10-03
HUE036524T2 (hu)	2018-07-30
AU2013315750B2 (en)	2018-07-12
TWI716649B (zh)	2021-01-21
TW201803593A (zh)	2018-02-01
US11001627B2 (en)	2021-05-11
US20180037642A1 (en)	2018-02-08
AU2018247244B2 (en)	2020-05-28
JP2015533797A (ja)	2015-11-26
RS57013B1 (sr)	2018-05-31
PE20200607A1 (es)	2020-03-10
EP2895188A1 (en)	2015-07-22
US10954294B2 (en)	2021-03-23
ES2657377T3 (es)	2018-03-05
DK2895188T3 (en)	2018-02-26
CL2015000572A1 (es)	2016-02-05
MX360044B (es)	2018-10-19
LT2895188T (lt)	2018-04-10
TWI609877B (zh)	2018-01-01
AR092532A1 (es)	2015-04-22
PL2895188T3 (pl)	2018-06-29
JP2019038817A (ja)	2019-03-14
CN104902914A (zh)	2015-09-09
MX2018012749A (es)	2020-11-12
KR102133699B1 (ko)	2020-07-14
KR20150056601A (ko)	2015-05-26
MX2015003090A (es)	2015-07-14
SG11201501460RA (en)	2015-04-29
US20140072560A1 (en)	2014-03-13
EP2895188A4 (en)	2016-05-25
US20190330325A1 (en)	2019-10-31
IL267452B (en)	2021-05-31
PE20150996A1 (es)	2015-08-01
JP2021100929A (ja)	2021-07-08
CN104902914B (zh)	2019-01-01
IL237311A0 (en)	2015-04-30
EP2895188B1 (en)	2017-11-15
US10947306B2 (en)	2021-03-16
PT2895188T (pt)	2018-02-08
SI2895188T1 (en)	2018-05-31
AU2013315750A1 (en)	2015-03-05
US10954295B2 (en)	2021-03-23
SMT201800163T1 (it)	2018-05-02
US10954293B2 (en)	2021-03-23
EA201590542A1 (ru)	2015-07-30
AU2013315750B9 (en)	2018-11-15
JP6913066B2 (ja)	2021-08-04
DOP2015000055A (es)	2015-04-30
US20190300601A1 (en)	2019-10-03
CO7400876A2 (es)	2015-09-30
HRP20180182T1 (hr)	2018-04-20
WO2014043103A1 (en)	2014-03-20
US20190300600A1 (en)	2019-10-03
ECSP15014138A (es)	2016-01-29
AU2018247244A1 (en)	2018-11-01
KR102250937B1 (ko)	2021-05-12
EA031324B1 (ru)	2018-12-28
CY1120062T1 (el)	2018-12-12
KR20200085937A (ko)	2020-07-15
CN110051823A (zh)	2019-07-26
CA2882551A1 (en)	2014-03-20